Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -74,207 | -49,150 | -20,396 | -4,476 | -81,152 |
| Depreciation Amortization | 8,294 | 7,873 | 7,451 | 433 | 14,445 |
| Income taxes - deferred | -1,143 | -586 | -586 | N/A | -3,448 |
| Accounts receivable | -3,619 | -2,343 | -3,860 | -3,111 | -508 |
| Accounts payable and accrued liabilities | 1,629 | 2,986 | 3,397 | 1,083 | -810 |
| Other Working Capital | -1,406 | -111 | -1,860 | -3,259 | -142 |
| Other Operating Activity | 56,252 | 28,452 | 7,255 | 3,631 | 44,125 |
| Operating Cash Flow | $-14,200 | $-12,879 | $-8,599 | $-5,699 | $-27,490 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,014 | N/A | N/A | N/A | -10,328 |
| Investing Cash Flow | $-2,014 | $N/A | $N/A | $N/A | $-10,328 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,000 | 2,000 | 1,971 | 2,000 | N/A |
| Debt Repayment | -2,200 | -2,200 | -2,200 | N/A | N/A |
| Common Stock Issued | 13,924 | 15,322 | 7,656 | N/A | 38,258 |
| Other Financing Activity | -65 | -65 | -21 | -21 | -5,055 |
| Financing Cash Flow | $13,659 | $15,057 | $7,406 | $1,979 | $33,203 |
| Exchange Rate Effect | -8 | -9 | N/A | N/A | N/A |
| Beginning Cash Position | 5,548 | 5,548 | 5,548 | 5,548 | 10,163 |
| End Cash Position | 2,985 | 7,717 | 4,355 | 1,828 | 5,548 |
| Net Cash Flow | $-2,563 | $2,169 | $-1,193 | $-3,720 | $-4,615 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,200 | -12,879 | -8,599 | -5,699 | -27,490 |
| Capital Expenditure | -2,014 | N/A | N/A | N/A | -10,328 |
| Free Cash Flow | -16,214 | -12,879 | -8,599 | -5,699 | -37,818 |